Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Trial Comparing the Safety and Efficacy of Two Different Oral VPV Doses With Placebo as Treatment for RV in Participants With COPD (Cardinal COPD)

8 settembre 2026 aggiornato da: Altesa Biosciences, Inc.

A Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial Comparing the Safety and Efficacy of Two Different Oral Vapendavir (VPV) Doses With Placebo as Treatment for Rhinovirus (RV) in Participants With Chronic Obstructive Pulmonary Disease (COPD)

Compare the safety and efficacy of two different oral vapendavir doses with placebo in order to determine the appropriate dose of vapendavir to reduce the severity and/or duration of respiratory symptoms associated with RV infections in patients with COPD.

Panoramica dello studio

Stato

Reclutamento

Condizioni

Intervento / Trattamento

Tipo di studio

Interventistico

Iscrizione (Stimato)

180

Fase

  • Fase 2

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

  • Regno Unito
      • Bromborough, Regno Unito, CH62 6EE
        • Reclutamento
        • FutureMeds Liverpool
        • Contatto:
          • FutureMeds Liverpool
      • Glasgow, Regno Unito, G20 7BE
        • Reclutamento
        • FutureMeds Glasgow
        • Contatto:
          • FutureMeds Glasgow
      • London, Regno Unito, NW10 2PB
        • Reclutamento
        • FutureMeds London
        • Contatto:
          • FutureMeds London
      • London, Regno Unito, RM1 1BH
        • Reclutamento
        • Clinicalysis
        • Contatto:
          • CLINICALYSIS
      • London, Regno Unito, SE6 4LF
        • Reclutamento
        • ProMed Innovations Clinical Research
        • Contatto:
          • ProMed Innovations Clinical Research
      • Milton Keynes, Regno Unito, MK15 0DU
        • Reclutamento
        • Bioluminux Clinical Research Milton Keynes
        • Contatto:
          • Bioluminux Clinical Research Milton Keynes
      • Wolverhampton, Regno Unito, WV9 5HB
        • Reclutamento
        • Bioluminux Clinical Research Wolverhampton
        • Contatto:
          • Bioluminux Clinical Research Wolverhampton
  • Stati Uniti
    • Alabama
      • Mobile, Alabama, Stati Uniti, 36608
        • Reclutamento
        • Velocity Clinical Research - Mobile
        • Contatto:
          • Velocity Clinical Research - Mobile
    • Arizona
      • Tempe, Arizona, Stati Uniti, 85281
        • Reclutamento
        • AMR Clinical - Tempe
        • Contatto:
          • AMR Clinical - Tempe
    • California
      • Inglewood, California, Stati Uniti, 90301
        • Reclutamento
        • 310 Clinical Research, LLC
        • Contatto:
          • 310 Clinical Research, LLC
      • Newport Beach, California, Stati Uniti, 92663
        • Reclutamento
        • NewportNativeMD, Inc.
        • Contatto:
          • NewportNativeMD, Inc.
      • San Diego, California, Stati Uniti, 92120
        • Reclutamento
        • Apex Clinical Research
        • Contatto:
          • Apex Clinical Research
    • Florida
      • Bradenton, Florida, Stati Uniti, 34209
        • Reclutamento
        • Synergy Health
        • Contatto:
          • Synergy Health
      • Miami Lakes, Florida, Stati Uniti, 33016
        • Reclutamento
        • MedQuest Translational Sciences
        • Contatto:
          • Medquest Translational Sciences
      • Miami Lakes, Florida, Stati Uniti, 33014
        • Reclutamento
        • VM Clintrials
        • Contatto:
          • VM Clintrials
      • Tamarac, Florida, Stati Uniti, 33321
        • Reclutamento
        • Metropolitan Clinical Research Center
        • Contatto:
          • Metropolitan Clinical Research Center
    • Georgia
      • East Point, Georgia, Stati Uniti, 30344
        • Reclutamento
        • Covenant Critical Pulmonary Care
        • Contatto:
          • Covenant Critical Pulmonary Care
    • Illinois
      • Naperville, Illinois, Stati Uniti, 60540
        • Reclutamento
        • Bioluminux Clinical Research Illinois
        • Contatto:
          • Bioluminux Clinical Research Illinois
    • Indiana
      • Valparaiso, Indiana, Stati Uniti, 46383
        • Reclutamento
        • Velocity Clinical Research - Valparaiso
        • Contatto:
          • Velocity Clinical Research - Valparaiso
    • Kentucky
      • Lexington, Kentucky, Stati Uniti, 40509
        • Reclutamento
        • AMR Clinical - Lexington
        • Contatto:
          • AMR Clinical - Lexington
    • Maryland
      • Lutherville, Maryland, Stati Uniti, 21093
        • Reclutamento
        • Patient First Clinical Trials (PFCTRIALS)
        • Contatto:
          • Patient First Clinical Trials (PFCTRIALS)
    • Michigan
      • Dearborn, Michigan, Stati Uniti, 48126
        • Reclutamento
        • Verexa Health
        • Contatto:
          • Verexa Health
      • Troy, Michigan, Stati Uniti, 48085
        • Reclutamento
        • Oakland Medical Research
        • Contatto:
          • Oakland Medical Research
    • Nevada
      • Las Vegas, Nevada, Stati Uniti, 89119
        • Reclutamento
        • AMR Clinical - Las Vegas
        • Contatto:
          • AMR Clinical - Las Vegas
    • New Jersey
      • Hamilton, New Jersey, Stati Uniti, 08690
        • Reclutamento
        • Bioluminux Clinical Research New Jersey
        • Contatto:
          • Bioluminux Clinical Research New Jersey
    • New York
      • Binghamton, New York, Stati Uniti, 13905
        • Reclutamento
        • Velocity Clinical Research - Binghamton
        • Contatto:
          • Velocity Clinical Research - Binghamton
      • Brooklyn, New York, Stati Uniti, 11226
        • Reclutamento
        • Brooklyn Clinical Research
        • Contatto:
          • Brooklyn Clinical Research
    • North Carolina
      • Kings Mountain, North Carolina, Stati Uniti, 28086
        • Reclutamento
        • CRC Kings Mountain
        • Contatto:
          • CRC Kings Mountain
    • Ohio
      • Columbus, Ohio, Stati Uniti, 43215
        • Reclutamento
        • Remington-Davis, Inc.
        • Contatto:
          • Remington-Davis, Inc.
      • Milford, Ohio, Stati Uniti, 45150
        • Reclutamento
        • Hometown Urgent Care - Milford
        • Contatto:
          • Hometown Urgent Care - Milford
    • Oklahoma
      • Edmond, Oklahoma, Stati Uniti, 73013
        • Reclutamento
        • Tekton Research
        • Contatto:
          • Tekton Research
    • Oregon
      • Medford, Oregon, Stati Uniti, 97504
        • Reclutamento
        • Velocity Clinical Research - Medford
        • Contatto:
          • Velocity Clinical Research - Medford
    • Pennsylvania
      • DuBois, Pennsylvania, Stati Uniti, 15801
        • Reclutamento
        • Clinical Research Associates of Central PA, LLC
        • Contatto:
          • Clinical Research Associates of Central PA, LLC l
      • Pittsburgh, Pennsylvania, Stati Uniti, 15423
        • Reclutamento
        • Preferred Primary Care Physicians - St. Clair
        • Contatto:
          • Preferred Primary Care Physicians - St. Clair
      • Sayre, Pennsylvania, Stati Uniti, 18840
        • Reclutamento
        • Guthrie Medical Group, PC
        • Contatto:
          • Guthrie Medical Group, PC
    • South Carolina
      • Anderson, South Carolina, Stati Uniti, 29621
        • Reclutamento
        • Velocity Clinical Research - Anderson
        • Contatto:
          • Velocity Clinical Research - Anderson
      • Rock Hill, South Carolina, Stati Uniti, 29732
        • Reclutamento
        • Clinical Research of Rock Hill
        • Contatto:
          • Clinical Research of Rock Hill
      • Spartanburg, South Carolina, Stati Uniti, 29303
        • Reclutamento
        • Velocity Clinical Research - Spartanburg
        • Contatto:
          • Velocity Clinical Research - Spartanburg
      • Union, South Carolina, Stati Uniti, 29379
        • Reclutamento
        • Velocity Clinical Research - Union
        • Contatto:
          • Velocity Clinical Research - Union
    • Texas
      • Lewisville, Texas, Stati Uniti, 75057
        • Reclutamento
        • Epic Clinical Research, LLC
        • Contatto:
          • Epic Clinical Research, LLC
      • Tomball, Texas, Stati Uniti, 77375
        • Reclutamento
        • Activian Clinical Research - Tomball
        • Contatto:
          • Activian Clinical Research - Tomball

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Adulto
  • Adulto più anziano

Accetta volontari sani

No

Descrizione

Inclusion

Sign informed consent for study participation and medical records release (if needed).

Male or female age ≥40 years and ≤85 years at the time of signing the informed consent at Screening.

If sexually active and/or of child-bearing potential (both females and males), must agree to use a highly effective form of contraception at the time of randomization until 30 days (females) or 90 days (males) after the last dose. Female participants may not use hormonal birth control as a sole method. Participants will be asked to commit to this criterion at screening even though it does not need to be implemented until treatment is received. See Section 11.2 below.

Confirmed diagnosis of COPD, defined as chronic cough, sputum production, and/or dyspnea with airflow obstruction which is not fully reversible (that is, post bronchodilator FEV1/FVC ratio <0.70 and post bronchodilator FEV1 ≥20% and <80% of predicted normal value).

History of AECOPD with at least 1 documented AECOPD within 1 year of Screening.

  • AECOPD is defined as an event characterized by dyspnea and/or cough and increased sputum purulence/change in sputum color that worsens over several days, and requires at least one of the following for at least 2 days:
  • Increase frequency or dose of beta agonist(s), oxygen, breathing treatments or chronic COPD medications (Mild Exacerbation)
  • Use of oral or systemic steroids (Moderate Exacerbation), or
  • Use of Antibiotics (Moderate Exacerbation), or
  • Emergency room visit or hospitalization (Severe Exacerbation). CAT score ≥10 at screening. Able to comply with all study requirements, including the use of a mobile application to complete daily PROs, perform nasal swabs at home, and able to assess when they have cold symptoms.

Interacts with people at least twice a week without a mask (e.g., grocery shopping, dinner with grandchildren, eating at a restaurant, going to the movies, etc.) or are living in a multigenerational home.

Inclusion criteria to be assessed only at Randomization:

If on stable COPD maintenance therapy this should be stable for at least 2 months prior to randomization. Changes allowed with Sponsor approval (i.e., change within same class due to financial considerations and clinically stable).

Clinically stable with no other exacerbations or respiratory infections (viral or bacterial) within 2 months prior to randomization.

The presence of RV (without a co-infection) at the time of randomization based on an approved molecular diagnostic test.

To be randomized, participants must have at least 3 E-RS scores completed within the previous 35 days to establish a PSB.

Exclusion

Pregnant or nursing or expected to become pregnant during the study period. Experiencing a current/active or prior exacerbation within 2 months of the Screening Visit (these participants should be rescreened after the exacerbation has been resolved for two months).

Participants with other primary causes of chronic airflow limitation:

- Including but not limited to: asthma alone (COPD with asthmatic features is acceptable), CF, bronchiolitis obliterans, fibrosis such as TB, IPF, non-CF bronchiectasis with multi-lobe involvement or other major respiratory diagnosis (e.g., allergic bronchopulmonary aspergillosis), etc.

Any disorder, for example, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, hematological, psychiatric impairment that is not medically stable, or other major physical impairment that is not considered by the investigator medically stable/controlled.

Participants with hepatitis B are excluded. Participants on a stable treatment for HIV can be permitted with permission from the medical monitor. Participants with hepatitis C should be treated and confirmed HCV RNA negative prior to enrollment. (Testing performed at the Screening Visit).

In the Investigator's opinion, the participant has any clinically significant laboratory abnormality including an abnormality that indicates clinically significant hematologic, hepatobiliary, or renal disease.

Presence of clinically significant out-of-range cardiac interval on the screening ECG including a QTcF > 450 msec (men) and a QTcF > 460 msec (women).

Medications or other non-medicinal products that could be impacted by CYP3A4, CYP2C8, or CYP2C19 induction and have serious complications for the participant within the treatment period.

Medications that are potent CYP2C8, CYP3A4 or CYP2C19 inducers that would reduce exposures of VPV.

Medications that are potent CYP2C8, CYP3A4, or CYP2C19 inhibitors that would increase exposures of VPV.

Medications that are substrates of MATE1, OAT3, P-gp, and BCRP for which elevated concentrations are associated with serious and/or life-threatening reactions.

Use of either of the following treatments:

  • Chronic oral/systemic steroids >10 mg per day (inhaled corticosteroids are permitted).
  • Continuous oxygen via nasal cannula of >2 L/min at the time of Screening or during the Asymptomatic Phase. (Participants on continuous oxygen may have the rate increased during physical exercise/ exertion or to cover any situationally induced decompensation, so long as the participant will resume a continuous rate of ≤2 L/min thereafter).

Participation in another investigational drug study within 5 half-lives prior to Screening and during the study is prohibited. This includes approved drugs being evaluated for a new indication. Observational studies are permitted.

Participants who have taken VPV in another clinical trial.

Exclusion criteria to be assessed only at Randomization:

It is already determined, based on the Investigator's clinical judgement, that the participant will likely need antibiotics and/or oral steroids at the Day 1 Randomization Visit.

On or within 7 days prior to randomization, there is another active diagnosed infection with viral or bacterial pathogens (i.e., urinary tract infection, cellulitis, etc.) that requires treatment.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Quadruplicare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Dosing Group 1 VPV 1000 mg
The first dose of 1,000 mg VPV will be taken at the study site with food once the Day 1 visit is completed. The second dose of 1,000 mg VPV will be taken at home the following morning with food. The subsequent 1,000 mg doses will be taken every 24 hours with food from the time of the second dose for a total of 7 doses.
Droga: VPV 1000 mg
Vapendavir 1000 mg
Altri nomi:
  • Vapendavir
Sperimentale: Dosing Group 2 VPV 500 mg
The first dose of 1,000 mg VPV will be taken at the study site with food once the Day 1 visit is completed. The second dose of 500 mg VPV will be taken at home the following morning with food. The subsequent 500 mg doses will be taken every 24 hours with food from the time of the second dose for a total of 7 doses.
Droga: VPV 1000 mg
Vapendavir 1000 mg
Altri nomi:
  • Vapendavir
Droga: VPV 500 mg
Vapendavir 500 mg
Altri nomi:
  • Vapendaivr
Comparatore placebo: Dosing Group 3 Placebo
The first dose of placebo will be taken at the study site with food once the Day 1 visit is completed. The second dose of placebo will be taken at home the following morning with food. The subsequent placebo doses will be taken every 24 hours with food from the time of the second dose for a total of 7 doses
Altro: Placebo
Placebo

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Evaluating Respiratory Symptoms (E-RS)
Lasso di tempo: Baseline Period/Asymptomatic Phase: Daily for 12 weeks Treatment/Follow-Up Periods: Daily for up to 42 days
11-item E RS collected as part of the 14-item EXAcerbations of Chronic pulmonary disease Tool (EXACT PRO®) scale, with data from the additional 3 items from the EXACT PRO scale used for exploratory purposes only. The PSB will be calculated as the mean of the E-RS scores collected in the -35 to -6 days prior to RV symptom onset. If the E-RS score has not returned to PSB at the time of Day 28 Visit, the participant will complete the E-RS daily until Day 42. The questions are asked about how the participant feels today and will be collected at night.
Baseline Period/Asymptomatic Phase: Daily for 12 weeks Treatment/Follow-Up Periods: Daily for up to 42 days

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Patient Global Impression of Severity (PGIS)
Lasso di tempo: Baseline Period/Asymptomatic Phase: Daily for 12 weeks Treatment/Follow-Up Periods: Daily for up to 42 days
The PGIS is one question, 'Please rate the overall severity of your respiratory symptoms today? (none, mild, moderate, severe, very severe).'
Baseline Period/Asymptomatic Phase: Daily for 12 weeks Treatment/Follow-Up Periods: Daily for up to 42 days
Wisconsin Upper Respiratory Symptom Survey - 11
Lasso di tempo: Treatment/Follow-up Periods: Daily for 28 days
The questions are asked about how the participant feels today or within the last 24 hours. The questionnaire will be completed at night.
Treatment/Follow-up Periods: Daily for 28 days
Change from Baseline in Respiratory System Resistance at 5 Hz (R5) Measured by Oscillometry
Lasso di tempo: Screening Visit, Day 1, Day 3, Day 7, Day 14, Day 28, Day 42
Respiratory system resistance at an oscillation frequency of 5 Hz, measured by oscillometry during unforced tidal breathing. R5 reflects total respiratory system resistance and is a measure of overall airway caliber. Values are reported as the mean of at least three technically acceptable measurements, performed according to the 2020 European Respiratory Society / American Thoracic Society technical standards for respiratory oscillometry. Unit of measure: cmH₂O·s/L.
Screening Visit, Day 1, Day 3, Day 7, Day 14, Day 28, Day 42
Change from Baseline in Respiratory System Resistance at 20 Hz (R20) Measured by Oscillometry
Lasso di tempo: Screening Visit, Day 1, Day 3, Day 7, Day 14, Day 28, Day 42
Respiratory system resistance at an oscillation frequency of 20 Hz, measured by oscillometry during unforced tidal breathing. R20 predominantly reflects large/central airway resistance, as higher-frequency oscillations do not penetrate the peripheral airways. Values are reported as the mean of at least three technically acceptable measurements, performed according to the 2020 European Respiratory Society / American Thoracic Society technical standards for respiratory oscillometry. Unit of measure: cmH₂O·s/L.
Screening Visit, Day 1, Day 3, Day 7, Day 14, Day 28, Day 42
Change from Baseline in Frequency Dependence of Resistance (R5-R20) Measured by Oscillometry
Lasso di tempo: Screening Visit, Day 1, Day 3, Day 7, Day 14, Day 28, Day 42
The difference between respiratory system resistance measured at 5 Hz and at 20 Hz (R5 minus R20), measured by oscillometry during unforced tidal breathing. R5-R20 is interpreted as an index of small airway dysfunction, with elevated values indicating heterogeneity of peripheral airway resistance. Values are calculated from the mean of at least three technically acceptable measurements at each frequency, performed according to the 2020 European Respiratory Society / American Thoracic Society technical standards for respiratory oscillometry. Unit of measure: cmH₂O·s/L.
Screening Visit, Day 1, Day 3, Day 7, Day 14, Day 28, Day 42
Change from Baseline in Respiratory System Reactance at 5 Hz (X5) Measured by Oscillometry
Lasso di tempo: Screening Visit, Day 1, Day 3, Day 7, Day 14, Day 28, Day 42
Respiratory system reactance at an oscillation frequency of 5 Hz, measured by oscillometry during unforced tidal breathing. X5 represents the elastic and inertive properties of the respiratory system at low frequency and becomes more negative with increased peripheral airway obstruction or reduced lung compliance. Values are reported as the mean of at least three technically acceptable measurements, performed according to the 2020 European Respiratory Society / American Thoracic Society technical standards for respiratory oscillometry. Unit of measure: cmH₂O·s/L.
Screening Visit, Day 1, Day 3, Day 7, Day 14, Day 28, Day 42
Change from Baseline in Area Under the Reactance Curve (AX) Measured by Oscillometry
Lasso di tempo: Screening Visit, Day 1, Day 3, Day 7, Day 14, Day 28, Day 42
The integrated area of the reactance curve from 5 Hz to the resonant frequency, measured by oscillometry during unforced tidal breathing. AX reflects the total elastic and inertive load of the respiratory system and is a sensitive composite index of peripheral airway dysfunction. Values are reported as the mean of at least three technically acceptable measurements, performed according to the 2020 European Respiratory Society / American Thoracic Society technical standards for respiratory oscillometry. Unit of measure: cmH₂O/L.
Screening Visit, Day 1, Day 3, Day 7, Day 14, Day 28, Day 42
Change from Baseline in Resonant Frequency (Fres) Measured by Oscillometry
Lasso di tempo: Screening Visit, Day 1, Day 3, Day 7, Day 14, Day 28, Day 42
The oscillation frequency at which respiratory system reactance equals zero, measured by oscillometry during unforced tidal breathing. Fres represents the frequency at which the inertive and elastic forces of the respiratory system are equal in magnitude and opposite in direction; it shifts to higher frequencies with peripheral airway obstruction. Values are reported as the mean of at least three technically acceptable measurements, performed according to the 2020 European Respiratory Society / American Thoracic Society technical standards for respiratory oscillometry. Unit of measure: Hz.
Screening Visit, Day 1, Day 3, Day 7, Day 14, Day 28, Day 42
Change from Baseline in Forced Expiratory Volume in 1 Second (FEV1) - Absolute Value
Lasso di tempo: Screening Visit, and Days 7, 14, 28 and 42
Forced expiratory volume in the first second of a maximal forced expiration following a full inspiration, measured by spirometry. FEV1 is a primary index of airflow obstruction. Values are reported as the highest acceptable value from at least three acceptable and two repeatable maneuvers, performed according to the 2019 European Respiratory Society / American Thoracic Society standards for spirometry. Unit of measure: liters.
Screening Visit, and Days 7, 14, 28 and 42
Change from Baseline in Forced Expiratory Volume in 1 Second (FEV1) - Percent Predicted
Lasso di tempo: Screening Visit, Day 7, Day 14, Day 28, Day 42
Forced expiratory volume in the first second expressed as a percentage of the predicted value for the participant's age, sex, height, and ethnicity using the Global Lung Function Initiative (GLI-2012) reference equations. Measured by spirometry according to the 2019 European Respiratory Society / American Thoracic Society standards. Unit of measure: percent of predicted (%).
Screening Visit, Day 7, Day 14, Day 28, Day 42
Change from Baseline in Forced Vital Capacity (FVC) - Absolute Value
Lasso di tempo: Screening Visit, Day 7, Day 14, Day 28, Day 42
Forced vital capacity, defined as the maximum volume of air exhaled with maximally forced effort from a position of maximal inspiration, measured by spirometry. Values are reported as the highest acceptable value from at least three acceptable and two repeatable maneuvers, performed according to the 2019 European Respiratory Society / American Thoracic Society standards for spirometry. Unit of measure: liters.
Screening Visit, Day 7, Day 14, Day 28, Day 42
Change from Baseline in Forced Vital Capacity (FVC) - Percent Predicted
Lasso di tempo: Screening Visit, Day 7, Day 14, Day 28, Day 42
Forced vital capacity expressed as a percentage of the predicted value for the participant's age, sex, height, and ethnicity using the Global Lung Function Initiative (GLI-2012) reference equations. Measured by spirometry according to the 2019 European Respiratory Society / American Thoracic Society standards. Unit of measure: percent of predicted (%).
Screening Visit, Day 7, Day 14, Day 28, Day 42
Change from Baseline in FEV1/FVC Ratio
Lasso di tempo: Screening Visit, Day 7, Day 14, Day 28, Day 42
The ratio of forced expiratory volume in 1 second (FEV1) to forced vital capacity (FVC), calculated from the highest acceptable FEV1 and FVC obtained during the same testing session. The FEV1/FVC ratio is the principal spirometric criterion used to identify airflow obstruction. Measured by spirometry according to the 2019 European Respiratory Society / American Thoracic Society standards. Unit of measure: ratio.
Screening Visit, Day 7, Day 14, Day 28, Day 42
Change from Baseline in Peak Expiratory Flow (PEF) - Absolute Value
Lasso di tempo: Screening Visit, Day 7, Day 14, Day 28, Day 42
Peak expiratory flow, defined as the highest flow achieved during a maximally forced expiration starting from a position of maximal inspiration, measured by spirometry. Values are reported as the highest acceptable value from at least three acceptable and two repeatable maneuvers, performed according to the 2019 European Respiratory Society / American Thoracic Society standards for spirometry. Unit of measure: liters per minute (L/min).
Screening Visit, Day 7, Day 14, Day 28, Day 42
Change from Baseline in Peak Expiratory Flow (PEF) - Percent Predicted
Lasso di tempo: Screening Visit, Day 7, Day 14, Day 28, Day 42
Peak expiratory flow expressed as a percentage of the predicted value for the participant's age, sex, height, and ethnicity using the Global Lung Function Initiative (GLI-2012) reference equations. Measured by spirometry according to the 2019 European Respiratory Society / American Thoracic Society standards. Unit of measure: percent of predicted (%).
Screening Visit, Day 7, Day 14, Day 28, Day 42

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Altesa Biosciences, Inc.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

1 maggio 2026

Completamento primario (Stimato)

15 novembre 2027

Completamento dello studio (Stimato)

15 novembre 2027

Date di iscrizione allo studio

Primo inviato

12 maggio 2026

Primo inviato che soddisfa i criteri di controllo qualità

22 maggio 2026

Primo Inserito (Effettivo)

28 maggio 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

10 settembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

8 settembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Termini MeSH pertinenti aggiuntivi

Altri numeri di identificazione dello studio

  • ALT-VPV-203

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi